Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Takeda Files NDA for Promising Acid-Related Disease Drug in Japan
March 3, 2014
- Novartis Files for Approval of Exforge OD Tablets
March 3, 2014
- Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
- Mizuho Projects 5% Upswing for FY2014 Operating Profit of 9 Major Japan Pharmas
February 28, 2014
- Nipro Opens Sales Subsidiary in Sweden
February 28, 2014
- Fujifilm Sets Up Chinese Subsidiary for Regenerative Medicine Business, Eyeing Provision of Epidermis Culturing Services by 2015
February 28, 2014
- All DPP-4 Inhibitors to Undergo Major Price Reductions Due to Market Expansion of Januvia/Glactiv; Re-pricing Could Affect SGLT-2 Inhibitors as Well
February 28, 2014
- 72 Drug Makers Provided 483 Billion Yen in Funding to Medical and Research Institutions in FY2012
February 27, 2014
- Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
- Shionogi Announces Reorganization to Boost R&D Capabilities
February 26, 2014
- Ranbaxy’s Toansa, Dewas Plants Voluntarily Suspend API Shipments Worldwide
February 26, 2014
- Takeda to Realign Japan Sales Team
February 25, 2014
- Ajinomoto Aims to Increase Operating Profit Rate to 10% in Pharmaceuticals Segment in FY2016 Under New Midterm Plan
February 24, 2014
- Multinational PIII Study of Revlimid for Follicular Lymphoma Starts in Japan: Celgene
February 24, 2014
- Sanofi to Begin Standalone Generic Operation in Japan
February 24, 2014
- Over 90% of Drug Makers Increasing Sales Rep Calls to Wholesalers Due to Imposed Restrictions
February 24, 2014
- ASKA Launches Leuplin Generic
February 21, 2014
- Diabetes Drug Sales Up 10% in 2013 Japan Market, Spurred by DPP-4 Inhibitors: IMS
February 21, 2014
- Plavix Tops Japan Ethical Drug Ranking, Sales Leap 14%: IMS
February 21, 2014
- US FDA Approves Droxidopa: DSP
February 20, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…